Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: a retrospective cohort study

Golbasi H., İNCE O., Golbasi C., Ozer M., Demir M., Yilmaz B.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY, cilt.39, sa.2, ss.157-163, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1080/01443615.2018.1504204
  • Dergi Adı: JOURNAL OF OBSTETRICS AND GYNAECOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.157-163
  • Anahtar Kelimeler: Intracytoplasmic sperm injection, gonadotropin-releasing hormone antagonist protocol, hCG-day, progesterone, progesterone/estradiol ratio, IN-VITRO FERTILIZATION, PREMATURE LUTEINIZATION, FOLLICULAR PHASE, ESTRADIOL RATIO, ONGOING PREGNANCY, EMBRYO TRANSFER, AGONIST, RATES, RISE, STIMULATION
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

This study investigates the predictive power of serum progesterone/estradiol (P/E-2) level for estimating the live birth rate in patients who had a serum progesterone (P) rate >= 1.5 ng/mL on the human chorionic gonadotropin (hCG) administration day and who received the gonadotropin-releasing hormone (GnRH) antagonist protocol and intracytoplasmic sperm injection (ICSI). This retrospective cohort study included 176 cycles. The P/E-2 ratio was lower in patients with a live birth (0.73 +/- 0.54) than those without a live birth (1.05 +/- 1.38), but the difference was not statistically significant (p = .158). According to the receiver operating characteristic curve analysis of the hCG day P/E-2 ratio, the area under the curve was 0.579 (95% confidence interval: 0.478 - 0.680, p = .158) for predicting live birth. In conclusion, this study suggests that a P/E-2 ratio is not a significant predictor of a live birth rate in the patients with an hCG-day serum progesterone level of >= 1.5 ng/mL undergoing GnRH antagonist ICSI cycles with a fresh embryo transfer.